JP2015536991A5 - - Google Patents

Download PDF

Info

Publication number
JP2015536991A5
JP2015536991A5 JP2015541932A JP2015541932A JP2015536991A5 JP 2015536991 A5 JP2015536991 A5 JP 2015536991A5 JP 2015541932 A JP2015541932 A JP 2015541932A JP 2015541932 A JP2015541932 A JP 2015541932A JP 2015536991 A5 JP2015536991 A5 JP 2015536991A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
disease
bone loss
gastrointestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015541932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015536991A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/069191 external-priority patent/WO2014074846A1/en
Publication of JP2015536991A publication Critical patent/JP2015536991A/ja
Publication of JP2015536991A5 publication Critical patent/JP2015536991A5/ja
Pending legal-status Critical Current

Links

JP2015541932A 2012-11-09 2013-11-08 骨量の減少の治療方法 Pending JP2015536991A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261724749P 2012-11-09 2012-11-09
US61/724,749 2012-11-09
PCT/US2013/069191 WO2014074846A1 (en) 2012-11-09 2013-11-08 Methods for the treatment of bone loss

Publications (2)

Publication Number Publication Date
JP2015536991A JP2015536991A (ja) 2015-12-24
JP2015536991A5 true JP2015536991A5 (https=) 2016-12-15

Family

ID=49679613

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015541932A Pending JP2015536991A (ja) 2012-11-09 2013-11-08 骨量の減少の治療方法

Country Status (4)

Country Link
US (1) US20150290171A1 (https=)
EP (1) EP2916869A1 (https=)
JP (1) JP2015536991A (https=)
WO (1) WO2014074846A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
CN104496951A (zh) * 2015-01-11 2015-04-08 景炜杰 一种氯代苯酐的制备方法
CN104892486B (zh) * 2015-06-25 2017-12-08 济南纽华医药科技有限公司 阿普斯特的晶型b+及其制备方法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3181549A1 (en) * 2015-12-17 2017-06-21 Zaklady Farmaceutyczne Polpharma SA Process for the preparation of apremilast
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN106008315A (zh) * 2016-06-16 2016-10-12 珠海联邦制药股份有限公司 一种阿普斯特晶型s及其制备方法
US10111882B2 (en) * 2016-09-14 2018-10-30 Gilead Sciences, Inc. SYK inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US7893101B2 (en) * 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
CA2718601A1 (en) * 2008-03-27 2009-10-01 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
CN103635188B (zh) * 2011-04-28 2017-03-22 细胞基因公司 使用pde4抑制剂用于治疗和控制自身免疫性疾病和炎性疾病的方法和组合物

Similar Documents

Publication Publication Date Title
JP2015536991A5 (https=)
JP6434482B2 (ja) 置換アシルアニリドおよびそれらの使用方法
ES2864671T3 (es) Composiciones que comprenden moduladores del receptor de esfingosina 1-fosfato (s1p)
Polly et al. The role of vitamin D in skeletal and cardiac muscle function
Sestak et al. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial
JP2018524577A5 (https=)
JP2017125021A (ja) Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法
JP2016529245A5 (https=)
RS65214B1 (sr) Modulatori integrisanog puta stresa
JP2014114296A5 (https=)
WO2011100505A3 (en) Methods and materials for producing transgenic artiodactyls
JP2021501779A (ja) 統合的ストレス経路の調節剤
JP2017511377A5 (https=)
JP2016522835A5 (https=)
KR20090030345A (ko) 선택적인 안드로겐 수용체 모듈레이터, 그 유사체와 유도체, 및 그의 용도
RU2010150406A (ru) Стабильная лекарственная форма для местного применения, содержащая вориконазол
Segal et al. Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery
KR20110081906A (ko) 치환된 아실아닐리드 및 그의 사용 방법
JP2014508752A5 (https=)
Prasad et al. Synthesis of fluorinated analogues of sphingosine-1-phosphate antagonists as potential radiotracers for molecular imaging using positron emission tomography
MY148878A (en) Stabilized amorphous forms of imatinib mesylate
US20190047932A1 (en) Nuclear receptor modulators and their use for the treatment and prevention of cancer
JP2018514517A (ja) レチノイン酸受容体−αアゴニストによる処置のための患者を層別化する方法
US9744149B2 (en) Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US20210236492A1 (en) Method for treating pancreatic cancer